EXAI News and Press, Exscientia Limited From 07/10/23

- Precision-designed potent and selective CDK7 inhibitor with potential for improved therapeutic index - - Preclinically discovered non-invasive PD biomarker to be confirmed alongside clinical trial - Exscientia plc (Nasdaq: EXAI) today announced that it has enrolled the first...

- Preclinical data from AI-optimized GTAEXS617 support potential for improved therapeutic index compared to other CDK7 inhibitors under development - - Parallel translational initiative to evaluate preclinically identified non-invasive PD biomarkers with potential to predict GTAEXS6...

Expanded leadership structure maintains nimble technology development across multitude of discovery and development functions Exscientia plc (Nasdaq: EXAI) announced today that it is expanding its technology management structure to accelerate application of Exscientia's innovative techn...

Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 11:20 a.m. PDT (7:20 p.m. BST). A live webcast of the fireside chat will be ...

2023-05-30 10:01:01 ET Gainers: HeartBeam ( BEAT ) +23% . Taro Pharmaceutical Industries ( TARO ) +22% . Akebia Therapeutics ( AKBA ) +19% . Corvus Pharmaceuticals ( CRVS ) +16% . Immix Biopharma ( IMMX ) +13% . Losers:...

2023-05-26 11:23:47 ET Shares of Exscientia (NASDAQ: EXAI) were up 30.3% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence . The artificial intelligence (AI)-driven precision medicine biotech stock is up more than 47% so far ...

2023-05-24 18:28:00 ET For a company operating in an area of great investor interest, even a mild quarterly earnings beat can really juice its stock price. That was the dynamic behind artificial intelligence (AI)-powered healthcare-solutions provider Exscientia 's (NASDAQ: EXAI) mor...

2023-05-24 14:15:24 ET Exscientia plc (EXAI) Q1 2023 Earnings Conference Call May 23, 2023 08:30 ET Company Participants Sara Sherman - Vice President of Investor Relations Andrew Hopkins - Chief Executive Officer Dave Hallett - Chief Scientific Officer Ben T...

2023-05-24 07:06:29 ET Exscientia press release ( NASDAQ: EXAI ): Q1 GAAP EPS of -$0.38. Revenue of $7.1M (-17.4% Y/Y). For further details see: Exscientia GAAP EPS of -$0.38, revenue of $7.1M

Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST / 8:30 a.m. EDT. ...